Lineage Cell Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
About Lineage Cell Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Lineage is a clinical-stage biotechnology company that develops allogeneic cell replacement therapies to treat serious degenerative conditions and traumatic injuries. Utilizing its proprietary AlloSCOPE manufacturing platform, the company differentiates pluripotent stem cells into specific, functional replacement cells designed to restore lost cellular activity. Its clinical-stage pipeline features OpRegen for geographic atrophy secondary to dry age-related macular degeneration and OPC1 for spinal cord injuries, alongside preclinical candidates such as ReSonance for auditory neuropathy. The company develops these off-the-shelf therapies for patients with cellular loss or impairment, providing ready-to-use formulations for administration by medical specialists such as retinal surgeons.
The company maintains corporate headquarters in Carlsbad, California, and operates an international research and production facility at the Jerusalem Bio Park in Israel. This Israeli site conducts all current good manufacturing practice processes, housing process development laboratories and cell banking operations. Lineage conducts clinical trials across the United States and Israel, including seventeen trial sites for its OpRegen study.
Summary of the business section of Lineage Cell Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lineage Cell Therapeutics, Inc.
- Founded
- 1990
- Headquarters
- Carlsbad, CA
- Address
- 2173 Salk Avenue, Suite 200 92008
- Phone
- (510) 521-3390
- Website
- www.biotimeinc.com
- Employees
- 77, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- California
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, San Diego, California
Stock & identifiers
- Ticker
- LCTX
- Exchange
- NYSE
- Shares outstanding
- 253M, Aug 3, 2026
- Public float
- $161.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 3-for-1, Oct 31, 1997
- SEC CIK
- 876343
- CUSIP
- 53566P109
- ISIN
- US53566P1093
- LEI
- 5299002BI4W22SDF8R25
- EIN
- 94-3127919
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian M. Culley | President and CEO, Director | 255,516 |
| Jill Ann Howe | Chief Financial Officer | 25,500 |
| George A. Samuel III | General Counsel and Secretary | 31,063 |
| Anula Jayasuriya | Director | 10,000 |
| Dipti Amin | Director | 35,000 |
| Deborah J. Andrews | Director | 34,720 |
| Angus C. Russell | Director | 92,220 |
| Neal C. Bradsher | Director | 104,136,455 |
| Michael H. Mulroy | Director | 298,555 |
| Broadwood Partners, L.P. | Director | 83,332,510 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brian Culley | $2.11M | $6.31M | $992.08K | $95 | – |
| FY2024 Brian Culley | $2.53M | $706.52K | $1.11M | $28 | – |
| FY2023 Brian Culley | $2.91M | $2.19M | $936.74K | $62 | – |
| FY2022 Brian Culley | $2.37M | -$135.37K | $1.16M | $66 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 77 employees, of which 22 were employed by Lineage and 55 were employed by CCN and work in Israel.”
Corporate history
Events identified from SEC filings